gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TNYAHealthcareBiotechnology

Tenaya Therapeutics, Inc. Common Stock (TNYA)

$0.3400−8.08%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$0.34▼ 75.36% in range
Nov 4, 2025Low $0.34 · High $1.54Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Tenaya Therapeutics closed at $0.34 on Nov 5, down 8.08%, within 0.0% of its 52-week closing low. Volume of 4.5M shares was 1.27× its 20-day average (above normal).

Split-adjusted performance: -36.3% over one month, -59.9% over six months, -75.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.11M, with a net margin of -3909.3%.

Short interest was 22.5M shares at the Oct 15 settlement, down 1.8% from the prior report (13.1% of float, 4.6 days to cover).

Market cap$77.5M227.9M shares
Revenue · quarter$1.1M—
Diluted EPS$-0.20—
P/E · TTM—P/S 58.0×
Net margin-3,909.3%Gross 100.0%
Dividend yieldNone
52-week range0.34 – 1.54−77.9% from high
Volume4.5M1.27× 20-day avg
Volatility · 60d79.1%Annualised
Short % of float13.1%4.6 days to cover
Net cash$78.1MCash $78.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −14.7%1M −36.3%3M −53.2%6M −59.9%YTD −52.2%1Y −75.4%3Y −81.3%5Y −98.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum20
Revenue growth—
Net margin15
Value (low P/E)—
Size31

Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.

Short interest

Details →
Shares short22.5M−1.8% vs prior
Days to cover4.6Settled Oct 15
% of float13.1%
Short vol. 10d57.1%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TNYATenaya Therapeutics$0.3400−8.08%−59.9%—−3909.3%—$77.5M
ATRAAtara Biotherapeutics$7.92−5.44%−20.3%−96.4%−767.3%—$79.4MCompare
TVGNTevogen$5.31−7.17%−29.0%———$89.0MCompare
CSBRChampions Oncology$4.79−0.83%−20.0%+8.8%−2.8%—$66.7MCompare
NMRANeumora Therapeutics$0.5111−9.70%−73.7%———$96.0MCompare
LENZLENZ Therapeutics$3.08−10.98%−68.3%−72.9%−915.2%—$96.8MCompare
BDTXBlack Diamond Therapeutics$1.69−11.05%−37.9%———$97.1MCompare
CGTXCognition Therapeutics$0.6405−6.26%−44.8%———$60.9MCompare
CRDFCardiff Oncology$0.7602−12.51%−52.5%−14.0%−8882.7%—$59.1MCompare

News about Tenaya Therapeutics

All news →
Tenaya Therapeutics Stock Jumps After New Alnylam DealBenzinga · Mar 5, 2026▲ Positive

Quick answers

What does Tenaya Therapeutics do?
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.
What is TNYA's market cap?
$77.50M, based on the Nov 5 close of $0.34.
Does Tenaya Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TNYA is sold short?
22.5M shares, 13.1% of float, as of Oct 15, 2026.
What sector is TNYA in?
Healthcare, in the Biotechnology industry.

About Tenaya Therapeutics

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

HQ: South San Francisco, CA70 employeesListed Jul 30, 2021tenayatherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology